Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL)~* WHO performance status of 2 or less.~* A life expectancy of at least one year.~* Greater than 18 years of age.~* Availability of CLL cells which can be used for DNA extraction and processing.~* A platelet count greater than 100 x 109/l.~* Ability to provide full informed consent.~Exclusion Criteria:~* Previous chemotherapy or radiotherapy.~* Presence of a monoclonal band on serum electrophoresis.~* Presence of clinically significant levels of anti-DNA antibodies, anti-muscle antibodies or rheumatoid factors or who have active autoimmune disease.~* Presence of antibodies to human immunodeficiency virus (HIV) and known carriers of hepatitis B or hepatitis C virus.~* Presence of other serious medical condition e.g. congestive heart failure.~* Presence of other malignancies.~* Pregnancy, lactation, or not using contraceptive measures.~* Concurrent use of other anti-cancer therapy.~* Patients allergic to tetanus vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).